Investments in Australian biotech and life sciences companies helped lift the Naos Emerging Long Short Equity Fund in March. The fund, which focuses exclusively on Australian equities, rose 9.33% in March, after a 11.83% gain in February.
“We don’t follow the market performance-wise, we look for big industry themes,” said fund manager Sebastian Evans.
Naos has been eyeing the biotech and life-sciences sector for more than three years. The Australian equities market is heavy on resource and financial-services companies and life sciences generally get lost in the shuffle, Evans said.
Two holdings in particular helped